It’s still pretty incredible $HIMS is down 44% even after:
1. $NVO de-risking + partnership
2. Multiple global acquisitions expanding DTC distribution network
3. Peptide arc, with Huberman saying HIMS was set to soar under these conditions
4. Entering a friendlier macro climate.
5. Short interest reaching unsustainable 36%+
The good news is: short interest can only be so much of the float… So it’s inherent buying pressure to cover over time, which does limit downside if fundamentals improves.